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Synthesis, cytotoxicity, DNA interaction and
cell cycle studies of trans-diiodophosphine
Pt(II) complexes†
Angeles Medrano,a Stephen M. Dennis,b Amparo Alvarez-Valdés,a Joseﬁna Perles,c
Tracey McGregor Mason*b and Adoracion G. Quiroga*a
Platinum complexes, bearing aliphatic amines and phosphine ligands in trans conﬁguration with iodide as
leaving groups, are synthesized and characterized. The crystal structure of trans-PtI2(isopropylamine)-
(PPh3) is reported. The complex bearing isopropylamine is demonstrated to be the best candidate as its
cytotoxic activity is comparable to or better than cisplatin. A remarkably higher interaction of the com-
plexes with DNA is reported as compared to the parent chlorido series. Cell cycle studies of the com-
plexes in six human cell lines are performed and also compared with the previous series.
Introduction
The discovery of new metallodrugs that can overcome the
unwanted eﬀects produced by cisplatin (currently the most
eﬃcient metallodrug in the clinic) has been extended in the
past decades to new platinum analogues with a design that
goes against the cis configuration requirement established by
cisplatin.1 The activity of trans platinum complexes of the form
trans-[PtCl2(L)(L′)] were reported in the early nineties, demon-
strating that synthetic variations in the coordinating ligands
may lead to new active species.2 Using aliphatic amines as
spectator ligands, our research group was also able to demon-
strate that active trans Pt(II) complexes were achievable.3 The
combination of aliphatic amines in the trans geometry with
other ligands has further proved that antitumor action is not
only possible but also can be increased in some cases.4 In fact,
phosphine ligands with hydrophobic character have been
shown to increase cytotoxicity, possibly caused by the enhance-
ment of cellular membrane transfer.5,6 The molecular mechan-
ism of trans complexes bearing aliphatic amines starts with
(as with most platinum complexes) the hydrolysis reaction.
Mechanistic studies in aqueous solution also revealed the
importance of the type of ligands bound to the platinum atom,7
but recent studies have demonstrated that using an iodide as
leaving group, particularly in the cis geometry,8 may have an
important role in the reactivity versus some biological targets.
The enhanced cytotoxicity achieved with trans complexes
bearing phosphine ligands and aliphatic amines, along with
our latest results using iodide as leaving groups, prompted us
to synthesize and study the combination of these variations;
the final compounds prepared are shown in Scheme 1.
The knowledge gained of tumor-associated cell cycle
defects have provided excellent information for the design of
anticancer compounds,9,10 but there are few studies of this
type that can particularly help in the design of metallodrugs.
It is known that normal cells treated with cisplatin produce
cell cycle arrest at the G2 phase of the cell cycle, which
coincides with the induction of Nucleotide Excision Repair,
the main pathway through which DNA-Pt lesions are
removed.11,12 It has also been reported that interstrand
adducts induced by some trans platinum compounds might
provide G1 and S-phase arrest, allowing only low levels of pro-
gression towards G2/M phase. DNA damage would then shunt
the cell toward apoptosis and cell death from G2/M.13,14
Scheme 1 General route of synthesis use to prepare the complexes.
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However, our data have indicated that some trans complexes
can induce a higher accumulation of cells into S phase which
does not translate into diﬀerential cytotoxic eﬀects,5 providing
evidence that further exploration is needed to determine if a
possible diﬀerential mechanism of action indeed exists.
With these novel complexes, we are interested to know if
the trans platinum complexes of Scheme 1 illicit the same cell
cycle arrest pattern as the previously reported complexes and




The synthesis of these three novel complexes was achieved in a
two-step procedure. First, the reaction of I2 with cis-
[PtCl2(PPh3)2] aﬀorded the dinuclear complex trans-[Pt2I2-
(µ-I)2(PPh3)2] in a good yield. Longer reaction times did not aid
in the formation of the dinuclear complex; on the contrary, the
isomerisation of the dinuclear complex takes place, and a
mixture of cis and trans platinum dinuclear complex was
detected (at −3853.5 and −4775.3 in the 195Pt NMR spectra).
This mixture can be used as the intermediate compound as
well in the synthesis of the final trans complexes.
Using cis-[PtI2(PPh3)2] as starting material allowed an
earlier detection of the dinuclear complex, but it never resulted
in a major species; as the reaction proceeded it produced a
complicated mixture of polynuclear complexes in which the
desired dinuclear complex was not visible after 24 h (monitor-
ing the reaction by 31P NMR). The second step is the cleavage
of the dinuclear complex by the direct reaction of isopropyl-
amine to produce complex 1, or by the slow addition of an
equivalent amount of NaOH to an aqueous solution of the
hydrochloric salt to produce complexes 2 and 3.
The characterization of these complexes, including the
intermediate complexes,16,17 was carried out by the techniques
of IR and 195Pt, 31P, 1H and 13C NMR. All of the microanalytical
data was consistent with the empirical formulas, and the
values of the coupling constant and chemical shifts of the 31P
and 195Pt NMR were in accordance to similar compounds
reported in the literature.5,18,19
Crystal structure of complex 1
The structure of complex 1 was determined by single crystal X-ray
diﬀraction. The molecular species trans-PtI2(ipa)(PPh3) displays a
Pt atom located in a distorted square planar environment. The
metal center is coordinated to one phosphorus, one nitrogen and
two iodine atoms in a trans disposition. Selected bond lengths
(Å) and angles (°) are summarized in the caption of Fig. 1.
We have found that the structure of compound 1 is one of
the few examples found in the literature, in fact there is only
one complex with a similar Pt–N distance in the literature,20
although in this case the geometry of the coordination
environment may be influenced by the interaction of the Pt(II)
with another nitrogen atom from the ligand. Pt–I distances,
however, fall within the range of the reported values (Pt–I =
2.567(1)–2.6763(6) Å).
Compared to the recently reported PtIV derivatives contain-
ing phosphines PtCl4(ipa)(PPh3),
21 Pt–N and Pt–P distances
found in compound 1 are very similar to the ones in the chlor-
ido derivative (Pt–N = 2.127(3) Å, and Pt–P = 2.2396(9) Å), and
longer than the ones found in analogous Pt(II) complexes
included in the CSD database, in which Pt–N distances range
from 2.051(4) to 2.079(7) Å, and Pt–P distances from 2.156(3)
to 2.225(2) Å.17,22,23
Cytotoxicity
The IC50 values of the three trans-complexes were determined
using a standard crystal violet staining assay (Table 1). Cispla-
tin was included as a positive control. The methylamine (3)
and dimethylamine (2) complexes were determined to be
universally ineﬃcacious, with IC50 values beyond the range of
concentrations applied. However, the isopropylamine (1) com-
pound resulted in values in the same range as cisplatin for 3
of the cell lines, A375, HCT116−/− and SKOV3. The 10-fold
lower cisplatin value for HCT116 wt reflects the known
increased sensitivity of the cell line to cisplatin compared to
the p53 null version of the cell line, HCT116(−/−).24 However
the HCT116 wt cell line showed a similar sensitivity to the iso-
propylamine complex compared to cisplatin. Because the IC50
values for the trans complexes did not follow the same pattern
in the HCT116 and HCT116(−/−) lines as cisplatin, it suggests
that the IC50 value of 27 μM for HCT116−/− occurred through
a diﬀerent mechanism of action and perhaps independent of
p53 status. The result for complex 1 in the lines of HCT116
(−/−), A375 and SKOV3 is lower than the value for cisplatin,
Fig. 1 Ellipsoid plot (50% probability) of complex 1. Hydrogen atoms
have been omitted for clarity. Selected bond lengths (Å): Pt1–I1 =
2.6255(5), Pt1–I2 = 2.5920(5), Pt1–N1 = 2.120(4), Pt1–P1 = 2.244(1);
Selected bond angles (°): I1–Pt1–I2 = 172.33(2), I1–Pt1–P1 = 91.51(3),
I1–Pt1–N1 = 87.8(2), I2–Pt1–P1 = 93.99(3), I2–Pt1–N1 = 86.5(2), N1–
Pt1–P1 = 177.4(1).
Table 1 Cytotoxic potency of Pt(II) complexes 1–3 on the diﬀerent cell
lines tested (IC50, μM)
Complex A375 HCT116 HCT116−/− T47D SKOV 3
1 20 >100 27 >100 22
2 >100 >100 >100 >100 >100
3 >100 >100 >100 >100 >100
CDDP 51 5 47 60 73
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suggesting a dissimilar mechanism that overcomes the known
resistance of SKOV3 and HCT116(−/−) towards cisplatin. This
is encouraging, as ERK1/2 phosphorylation occurs in A375 cells,
oﬀering protection from cisplatin-mediated apoptosis.11,25,26 In
all cases it is worth pointing out that the complex with the most
promise as an antitumor drug is the complex with the most
bulky aliphatic amine ligand. In addition, the larger size of the
PPh3 spectator ligand has been previously discussed to be
responsible for increased DNA distortion,5 additionally the
complex with the most promising IC50 value is the complex
with the most bulky isopropylamine ligand (Table 1).
Binding studies using DNA models: 9-EtG and pBR322
We have studied the reactivity of the most active compound, 1
with 9-ethyl guanine (9-EtG) to model the reactions with DNA
purine nucleobases. 9-EtG has been extensively used as a DNA
model for metallodrugs studies,27,28 including iodido com-
plexes bearing aliphatic amines,29 and has become a good
model to allow for the comparison with these new phosphine
diiodido derivatives. In our studies, the reaction of complex 1
with 9-EtG was monitored by 1H NMR spectroscopy as
described in the ESI† and recorded at diﬀerent times over
24 hours incubation at 37 °C (Figure SM-B1).
The solubility of the new iodido complexes is higher than
the chlorido derivatives,5 but in spite of this improved solubi-
lity, the problem of the concentration hasn’t been fully over-
come, as can be seen in the low resolution of the aromatic
area of the spectra in Figure SM-B1. When following the
changes in the H8 peak of 9-EtG, which is the most aﬀected
signal when the platination of the base takes place at N7, we
can detected a broad signal which arises at ca. 8.00 ppm
corresponding to the H8 resonance of any possible new
adduct. The spectra, as previously mentioned, showed low
resolution probably caused by speciation. Another feature that
supports speciation is the new signal at 6.4 ppm, which
possibly belongs to the H8 of an additional species. The low
concentration of the spectra does not allowed further exper-
iments to be recorded, but it has been reported previously that
H8 of 9-EtG can be extremely unshielded when is wedged
between bulky groups.27
Most importantly, from the obtained spectra, we are sure
that no isopropylamine free ligand is shown at 0.9 ppm
(methyl group from free ipa). So the new complexes react
versus DNA in a classic manner, losing the iodido ligands.
Moreover we can clearly see that the reactivity of this complex
is much slower than the iodido reported previously,29,30 which
after only 2 hours most of the 9EtG-free signal was already
reacted. Complex 1, on the other hand, does show 9EtG-free
(H8) signal as a major species, after 24 hours.
The DNA unwinding assay is a standard assay used to deter-
mine DNA interactions with platinum compounds. It is known
that the binding of cisplatin introduces severe distortion in
the DNA helix in the form of bending and unwinding of nega-
tive supercoils.
In this work, supercoiled pBR322 DNA was incubated with
increasing amounts of complexes 1–3 and the amount of
unwinding at those complex : DNA ratios (ri) was compared. All
three complexes caused negatively supercoiled plasmid DNA to
migrate more slowly on an agarose gel, confirming that negative
supercoils are removed as the complexes bind. Complex 1
appears to completely relax the supercoils at an ri of 0.1, while
the other complexes don’t result in complete unwinding at these
concentrations. This coincides with the toxicity data that follows
showing the lack of eﬃcaciousness of complexes 2 and 3 (Fig. 2).
However we must be careful making these kinds of com-
parisons because the active chloride parent complexes showed
less distortion under the same conditions, yet demonstrated
high cytotoxicity.
Cell cycle studies
Once the IC50 values were established for the various cell lines
studied, a fixed concentration of complex was used to treat cul-
tures in preparation for cell cycle analysis. They were treated
exactly as cells used for IC50 establishment, but were fixed, PI
(propidium iodide) stained and analysed for DNA/cell content.
In the SKOV3 cell line, the cell cycle distribution was similar
for all complexes tested and cisplatin (Fig. 3), while the trans
complexes showed a lower overall G0/G1 accumulation.
A similar result in SKOV3 was seen with other trans-dichloro
Pt(II) complexes with phosphine ligands prepared by this
group.5 The HCT116 wt cell line, showed a similar result. In
comparison, however, the HCT116−/− cell line treated with
cisplatin showed its typical G2/M accumulation,13,31 while
none of the trans complexes showed comparable accumu-
lation. Also notable is the increase in G0/G1 accumulation in
A375 cells treated with trans complexes relative to cisplatin.
Also interestingly, this was the only cell line with which a sub-
G1 peak was noted with cisplatin treatment.
This presence of hypodiploid DNA in the histogram is sug-
gestive of apoptosis, but should be interpreted with caution.32
This particular assay is incapable of definitively reporting
apoptosis, however we can interpret the lack of a clear sub-G1
Fig. 2 Agarose gel electrophoresis of pBR322 plasmid treated with the
trans PtII complexes. Lane 1: Marker and lane 2: DNA of control plasmid.
Plasmid DNA incubated at ri = 0.01, 0.05 and 0.1 with complexes
1 (lanes 3 to 5), complex 2 (lanes 6 to 8) and complex 3 (lanes 9 to 11).
oc = open circular DNA form; ccc = covalently closed circular DNA.
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peak in the histogram of any of the trans-treated cells as indi-
cation of a clear diﬀerence in the mechanism of action from
cisplatin in A375 melanoma cells.
It has been reported that longer treatment eventually results
in cell cycle arrest as the cellular distribution profile changes
over time, depending on repair deficiencies that may or may not
exist in a particular cell line.31 However, in our previous experi-
ence, in we have seldom been able to find information or values
that could help us to detect such diﬀerences with longer treat-
ments.15 In this regard we are convinced that additional work
can and should be done, and our plan is to use these com-
pounds or some with similar and small structural variations to
obtain more valuable information into possible diﬀerences in
the mechanism of action of trans-PPh3 complexes.
Conclusion
Complexes with phosphine and aliphatic amines were syn-
thesized and studied. The results showed similar cytotoxicity
to cisplatin for complex 1, and such studies can be correlated
to the unwinding pattern shown versus DNA. The structural
studies of complex 1 represent a good candidate with which to
evaluate the diﬀerences with similar complexes made pre-
viously. The biological studies indicates that complex 1
showed the most promising results versus cancer cell lines
tested and it is the best candidate for further study into the
biological action of these complexes.
Experimental methods
Chemistry
The starting material were prepared following a procedure pre-
viously described in our laboratory for cis-[PtCl2(PPh3)2] and
trans-[Pt2I2(µ-I)2(PPh3)2] was synthesized as following:
A solution of I2 (208.1 mg, 0.82 mmol) in 6 mL of CH2Cl2
was added in small portions (1.5 mL) to a solution of complex
cis-[PtCl2(PPh3)2] (500 mg, 0.63 mmol) in CH2Cl2 and heated at
50 °C. After 6 days, the reaction was cooled down at room
temperature and the resulting red solid was filtrated, washed
with cool CH2Cl2 and vacuum dried. Red Solid. Yield: 63%
Elemental analysis: calculated C36H30I4P2Pt2·0.7CH2Cl2, C:
29.75%, H: 2.14%; found: C: 29.61%, H: 2.18%. δH(300 MHz;
DMSO-d6) 7.67 (m, 6H, Hortho), 7.52 (m, 9H, Hmeta–para).
δC(75.47 MHz; DMSO-d6) 134.7(Cortho), 128.6(Cmeta), 131.6
(Cpara). δP(300 MHz; DMSO-d6) 18.14 ( JP–Pt = 3561.24 Hz).
δPt(64.53 MHz; DMSO-d6; Na2PtCl6) −4319.22. ( JPt–P =
3805.18 Hz). MS (ESI): 1444.72 amu [M + Na]+.
Method a: trans-[PtI2(amine)(PPh3)] where amine:
methylamine and dimethylamine
A solution of 2 equivalents of NaOH in water was added to a
mixture of trans-[Pt2I2(µ-I)2(PPh3)2] (80 mg, 0.056 mmol) and
the desired amine: methylamine hydrochloride (7.5 mg,
112 mmol), dimethylamine hydrochloride (9.12 mg,
0.112 mmol) in chloroform and stirred in darkness at room
temperature for 2 days. The resulting orange solution was
dried to a crude solid which was purified by redissolving in
diethyl ether. The final solution was left at room temperature
to slowly evaporate and the final product was isolated as an
orange solid.
trans-[PtI2(dma)(PPh3)]. Orange solid. Yield: 71%. Elemen-
tal analysis: calculated C20H22NI2PPt·(CH3)2CO: C: 33.92%, H:
3.47%, N: 1.72%. CHN; found: C: 34.53%, H: 3.34%, N: 1.63%.
δH(300 MHz; acetone-d6) 7.72 (m, 6H, Hortho), 7.42 (m, 9H,
Hmeta–para), 4.68 (bs, 1H, NH), 2.80 (d, 6H, CH3-dma).
δC(75.47 MHz; acetone-d6) 135.1(Cortho), 127.5(Cmeta), 130.5
(Cpara), 42.2(CH3-ma). δP(300 MHz; acetone-d6) −1.2 ( JP–Pt =
3262.22 Hz). δPt(64.53 MHz; acetone-d6; Na2PtCl6) −4933.6
( JPt–P = 3262.37 Hz). MS (ESI): 755.9 amu [M]
+.
trans-[PtI2(ma)(PPh3)]. Orange solid. Yield: 60%. Elemental
analysis: calculated C19H20NI2PPt·0.6CHCl3·0.6C4H10O: C:
30.64%, H: 3.11%, N: 1.62%. CHN; found: C: 30.97%, H:
2.72%, N: 1.62%. δH(300 MHz; CDCl3) 7.71 (m, 6H, Hortho),
7.40 (m, 9H, Hmeta–para), 2.72 (d, 3H, CH3-ma, JH–H = 7 Hz).
δC(75.47 MHz; CDCl3) 135.5(Cortho), 128.6(Cmeta), 131.4(Cpara),
24.5(CH3-ma). δP(300 MHz; CDCl3) 0.9 ( JP–Pt = 3412.32 Hz).
δPt(64.53 MHz; CDCl3; Na2PtCl6) −5045.5 ( JPt–P = 3411.31 Hz).
Method b: trans-[PtI2(amine)(PPh3)] where amine:
isopropylamine
A mixture of trans-[Pt2I2(µ-I)2(PPh3)2] (80 mg, 0.056 mmol) and
isopropylamine (130 μl, 1.5 mmol) in chloroform was stirred
in darkness at room temperature for 2 days. The resulting
orange solution was dried to a crude solid which was purified
by redissolving in diethyl ether. The final solution was left at
room temperature to slow evaporation to isolate the final
product as an orange solid.
trans-[PtI2(ipa)(PPh3)]. Orange solid. Yield: 71%. Elemental
analysis calculated for C21H24I2NPPt·1.3C4H10O: C: 36.31%, H:
4.03%, N: 1.62% CHN found: C: 36.99%, H: 3.52%, N: 1.85%.
Fig. 3 Percent of cells at each cell cycle phase after treatment with
trans-platinum (II) complexes 1–3 and cisplatin.
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δH(300 MHz; CDCl3) 7.73 (m, 6H, Hortho), 7.71 (m, 9H,
Hmeta–para), 3.84 (sp, 1H, CH-ipa), 3.51 (bs, 2H, NH2), 1.38 (d,
6H, CH3-ipa). δC(75.47 MHz; CDCl3) 135.1(Cortho), 132.8(Cipso)
130.6(Cpara), 127.5(Cmeta), 40.0 (CH-ipa), 25.4(CH3-ipa).
δP(300 MHz; CDCl3) 0.9 ( JP–Pt = 3407.28 Hz). δPt(64.53 MHz;
CDCl3; Na2PtCl6) −5004.9 ( JPt–P = 3407.28 Hz). MS (MALDI-
TOF): 771 amu [M − H]+.
Biology
pBR322 binding studies and conditions. The DNA binding
studies were performed in a total volume of 20 μl. The DNA ali-
quots containing 8 μL of DNA-pBR322 (10 ng mL−1 stock) in
10 mM Tris-HCl (pH 7.6) and 1 mM EDTA were incubated with
the platinum compounds at several ri values (0.001 to 0.1)
using the corresponding amount of platinum from either a
5 μM or 50 μM stock solution. The samples were incubated at
37 °C for 24 h, after which time 2 μL of a loading dye contain-
ing 50% glycerol, 0.25% bromophenol blue and 0.25% xylene
cyanol was added. The entire sample (20 μL) was loaded in the
wells of a 0.8% agarose gel. Electrophoresis was carried out for
a period of 2.5 h at approximately 50 V. After electrophoresis,
the gel was immersed in 800 mL of Millipore water containing
64 μL of a 10 mg mL−1 stock solution of ethidium bromide for
30 minutes to stain the DNA.
Cytotoxicity. The following cell lines were used in this work:
A375, human malignant melanoma and SKOV3 human
ovarian adenocarcinoma (both from ATCC, Manassas, VA);
T47D, breast duct epithelial carcinoma, HCT116, human colo-
rectal carcinoma (both a gift from Paul Miller, Johns Hopkins
University); and HCT116(−/−), (a gift from Margaret Wear, Uni-
formed Services University of the Health Sciences, Bethesda,
MD) All cell lines were maintained in monolayers in humidi-
fied air with 5% CO2 at 37 °C in Dulbecco’s Modified Eagle
Media-α (DMEM-α) with the exception of HCT116(−/−) and
T47D, which were maintained in RPMI media. All media con-
tained 10% fetal bovine serum, and 1× streptomycin/ampi-
cillin. To determine cytotoxicity, cells were seeded at a density
of 4000 cells per well in a 96-well plate. The cells were allowed
to attach and recover for 48 hours and then were treated in
triplicate with 0.2 mL of increasing concentrations of drug
diluted in media. Compounds 1–3 were diluted from a 10 mM
stock of compound freshly dissolved in DMSO; while cisplatin
stock was prepared to 5 mM in PBS (phosphate buﬀered
saline). The compound remained on the cells for 2 hours, after
which the media containing drug was aspirated and replaced
with fresh media. After another 24 hours, the cells were
washed twice with PBS, then fixed in 10% glutaraldehyde for
15 minutes. The cells were again washed twice with PBS, then
stained with 0.25% crystal violet at 37 °C for 15 minutes. They
were then extensively washed with PBS and the remaining dye
was solubilized using 0.200 mL 33% acetic acid. The absor-
bance of purple color was quantified at 595 nm using a Tecan
Sunrise Absorbance plate reader.
Cell cycle analysis. To conduct cell cycle analysis, all cell
lines were seeded at a density of 75 000 cells per well in a
12-well plate. The cells were allowed to attach and recover for
24 hours and then were treated with 1.0 mL of 50 or 10 μM
drug diluted in media. Compounds 1–3 were diluted from
100 mM stock of compound freshly dissolved in DMSO; while
cisplatin was administered at 50 μM concentration and was
diluted from a stock that was prepared to 5 mM in PBS. The
compound remained on the cells for 48 hours, after which the
media containing drug was aspirated and replaced with fresh
media. After treatment, the cells were washed and trypsinized
to detach them from the plate. The cells were suspended in
1 mL fresh media and transferred to a polystyrene culture
tube. The cells were pelleted at 450g for 5 minutes in a swing
bucket centrifuge and washed twice with 1 mL of PBS. After
pelleting, the washed cells they were resuspended in 0.25 mL
PBS to which 2.25 mL ice cold 70% ethanol was added slowly
with vortexing. This suspension remained at −20 °C until cell
sorting. Just prior to cell cycle analysis, the cells were pelleted
at 450g for 5 minutes, washed with 1 mL PBS and pelleted
again. To the cell pellet, 0.2 mL of Guava Cell Cycle Reagent
(Millipore) was added, and the cells were allowed to incubate
at room temperature for 30 minutes in the dark. The samples
were analysed for cell cycle distribution using a Guava Easy
Cyte Flow Cytometer and Guava CytoSoft Analysis software.
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